Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. (KTTAW) Stock Overview
Explore Pasithea Therapeutics Corp.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
70K
P/E Ratio
-0.00
EPS (TTM)
N/A
ROE
-1.48%
KTTAW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Pasithea Therapeutics Corp. (KTTAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 44.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 70K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.